PMID- 35200579
OWN - NLM
STAT- MEDLINE
DCOM- 20220324
LR  - 20220324
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Print)
IS  - 1198-0052 (Linking)
VI  - 29
IP  - 2
DP  - 2022 Feb 10
TI  - Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in 
      Real-Life Setting: An Efficacy and Safety Monocentric Study.
PG  - 945-955
LID - 10.3390/curroncol29020080 [doi]
AB  - BACKGROUND: Pembrolizumab is approved for patients with metastatic urothelial 
      carcinoma (UC) who progressed under platinum therapy. The aim of this study was 
      to assess the efficacy and safety of pembrolizumab in a cohort of real-life UC 
      patients. METHODS: This retrospective, observational study included advanced UC 
      patients treated with pembrolizumab in a single institution in France. The 
      co-primary endpoints were overall survival (OS) and progression-free survival 
      (PFS) at 6 months. Secondary endpoints were objective response rate (ORR), 
      duration of response (DOR), disease control rate (DCR) and safety. RESULTS: 78 
      patients were included in the study. The median OS was 7.3 months (3.8-12.2). The 
      estimated OS rate at 6 months was 61.5% (50.5-72.6). The median PFS was 3.1 
      months (1.4-7.2). The estimated PFS rate at 6 months was 42.3% (31.1-53.5). The 
      best ORR was 35.9%. The mean DOR was 95.5 days. The DCR was 30.8%. The most 
      common treatment-related adverse events (AEs) of any grade were fatigue (46.2%), 
      diarrhea (11.5%), pruritus (10.3%) and nausea (9.0%). There were no grade 3 AEs 
      that occurred with an incidence of 5% or more. CONCLUSION: Our results confirmed 
      those of randomized clinical trials concerning the treatment with pembrolizumab 
      in patients with advanced UC that progressed after platinum-based chemotherapy.
FAU - Dang, Elodie
AU  - Dang E
AD  - Pharmacy Department, Foch Hospital, 92150 Suresnes, France.
FAU - Vallee, Alexandre
AU  - Vallee A
AD  - Clinical Research and Innovation Department, Foch Hospital, 92150 Suresnes, 
      France.
FAU - Lepage-Seydoux, Coralie
AU  - Lepage-Seydoux C
AD  - Pharmacy Department, Foch Hospital, 92150 Suresnes, France.
FAU - Sejean, Karine
AU  - Sejean K
AD  - Pharmacy Department, Foch Hospital, 92150 Suresnes, France.
FAU - Bonan, Brigitte
AU  - Bonan B
AD  - Pharmacy Department, Foch Hospital, 92150 Suresnes, France.
FAU - Abraham, Christine
AU  - Abraham C
AD  - Medical Oncology Department, Foch Hospital, 92150 Suresnes, France.
FAU - Beuzeboc, Philippe
AU  - Beuzeboc P
AD  - Medical Oncology Department, Foch Hospital, 92150 Suresnes, France.
FAU - Ratta, Raffaele
AU  - Ratta R
AUID- ORCID: 0000-0002-2445-415X
AD  - Medical Oncology Department, Foch Hospital, 92150 Suresnes, France.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220210
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Carcinoma, Transitional Cell/drug therapy/pathology
MH  - Humans
MH  - Retrospective Studies
MH  - *Urinary Bladder Neoplasms/drug therapy
PMC - PMC8870973
OTO - NOTNLM
OT  - immune checkpoint inhibitors
OT  - immunotherapy
OT  - pembrolizumab
OT  - programmed cell death 1 receptor
OT  - urinary bladder neoplasms
COIS- The authors declare no conflict of interest.
EDAT- 2022/02/25 06:00
MHDA- 2022/03/25 06:00
PMCR- 2022/02/10
CRDT- 2022/02/24 12:20
PHST- 2022/01/11 00:00 [received]
PHST- 2022/01/31 00:00 [revised]
PHST- 2022/02/08 00:00 [accepted]
PHST- 2022/02/24 12:20 [entrez]
PHST- 2022/02/25 06:00 [pubmed]
PHST- 2022/03/25 06:00 [medline]
PHST- 2022/02/10 00:00 [pmc-release]
AID - curroncol29020080 [pii]
AID - curroncol-29-00080 [pii]
AID - 10.3390/curroncol29020080 [doi]
PST - epublish
SO  - Curr Oncol. 2022 Feb 10;29(2):945-955. doi: 10.3390/curroncol29020080.